Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2012

Sadness in the SUN: Using computerized screening to analyze
correlates of depression and adherence in HIV-infected adults in
the united states
Ellen M. Tedaldi
Temple University

Mary van den Berg-Wolf
Temple University

James Richardson
Cerner Corporation

Pragna Patel
Centers for Disease Control and Prevention, Atlanta

Marcus Durham
Centers for Disease Control and Prevention, Atlanta

See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Tedaldi, Ellen M.; van den Berg-Wolf, Mary; Richardson, James; Patel, Pragna; Durham, Marcus; Hammer,
John; Henry, Keith; Metzler, Sara; Onen, Nur; Conley, Lois; Wood, Kathy; Brooks, John T.; and Buchacz, Kate,
,"Sadness in the SUN: Using computerized screening to analyze correlates of depression and adherence in
HIV-infected adults in the united states." AIDS Patient Care and STDs. 26,12. 718-729. (2012).
https://digitalcommons.wustl.edu/open_access_pubs/3269

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Ellen M. Tedaldi, Mary van den Berg-Wolf, James Richardson, Pragna Patel, Marcus Durham, John
Hammer, Keith Henry, Sara Metzler, Nur Onen, Lois Conley, Kathy Wood, John T. Brooks, and Kate Buchacz

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/3269

AIDS PATIENT CARE and STDs
Volume 26, Number 12, 2012
ª Mary Ann Liebert, Inc.
DOI: 10.1089/apc.2012.0132

Sadness in the SUN: Using Computerized Screening
to Analyze Correlates of Depression and Adherence
in HIV-Infected Adults in the United States
Ellen M. Tedaldi, M.D.,1 Mary van den Berg-Wolf, M.D.,1 James Richardson, M.S.,2
Pragna Patel, M.D., M.P.H.,3 Marcus Durham, M.P.H.,3 John Hammer, M.D.,4 Keith Henry, M.D.,5
Sara Metzler, R.N.,6 Nur Önen, M.D.,7 Lois Conley, M.P.H.,3 Kathy Wood, B.S.N.,2
John T. Brooks, M.D., M.P.H.,3 Kate Buchacz, Ph.D.,3 and the SUN Study Investigators*

Abstract

We used a standardized screening tool to examine frequency of depression and its relation to antiretroviral medication adherence among HIV-infected persons on highly active antiretroviral therapy (HAART) in the Study to
Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study). This is a prospective
observational cohort of 700 HIV-infected patients enrolled between March 2004 and June 2006 in four U.S. cities, who
completed a confidential audio computer-assisted self-interview [ACASI] with behavioral risk and health-related
questions at baseline and 6-month follow-up visits, including the nine-question PRIME-MD depression screener and
a validated 3-day antiretroviral adherence question. Among 539 eligible participants receiving HAART, 14% had
depression at baseline (22% women, 12% men). In multivariable analysis using generalized estimating equations
(GEE) to account for repeated measurements through 24 months of follow-up, persons who reported depression on a
given ACASI were twice as likely to report nonadherence to antiretrovirals on the same ACASI (Odds ratio [OR]
2.02, 95% CI: 1.15, 3.57] for mild/moderate depression versus none); such persons were also less likely to have HIV
viral load < 400 copies/mL. Self-administered computerized standardized screening tools can identify at-risk individuals with depression who may benefit from interventions to improve antiretroviral adherence.

Introduction

D

epression occurs frequently in HIV-infected persons. Reported rates of depression and depressive
symptoms range from 22 to 54 percent in HIV-infected communities in the United States and typically exceed the prevalence found in the general population.1–6
The frequency of depression does not appear to vary according to the use of highly active antiretroviral therapy
(HAART). In both the pre and post HAART era, depression as
well as other disorders of anxiety and dysthymia are common.6–8
Despite the high prevalence of depression and depressive symptoms among HIV-infected persons, these conditions remain under-diagnosed.9,10 For these individuals, the

consequences of unrecognized and untreated depression can
be significant and include increased mortality, diminished
quality of life, and impaired adherence to antiretroviral
therapy.11–18 A recent meta-analysis documented an association between depression and nonadherence to antiretroviral
therapy across different study populations, including some
that represented diverse and contemporary HIV cohorts with
a significant representation of women and persons of color.19
As the current U.S. HIV epidemic disproportionately impacts
communities of color, the relationship of gender and ethnicity
to depression is important to document and understand.20–26
Depression and depressive symptoms do seem to occur
more frequently in HIV-infected women compared to
men.3,15,16 Women living with HIV infection often have many
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SADNESS IN THE SUN
sociodemographic and lifestyle characteristics associated with
depression, such as poverty, isolation, higher rates of smoking, traumatic life events, and substance abuse.2,27–30 Several
reports indicate that cellular immune responses in women
may be altered with depression.29 Fortunately, treatment of
depression pharmacologically or through other behavioral
interventions can be beneficial with demonstrated improved
clinical outcomes and HAART adherence;12,31–36 however,
differential use of antidepressants has been documented.37–39
The relationship of depression and its treatment and
HAART adherence is a dynamic one and longitudinal evaluations of HIV-infected persons in the evolving chronic
disease model of care are needed. Assessing depression in
HIV-infected persons can be done through structured interviews or standardized screening instruments that may be selfadministered or done electronically.19,40–45 The PRIME-MD
Patient Health Questionnaire-9 (PHQ-9) is a widely used instrument for depression screening that has been incorporated
into primary care settings to identify the presence and severity
of depression.43,45,46 The ease of its administration enables the
PHQ-9 to be used in long-term patient cohorts.
Using longitudinal data from the prospective SUN Study, a
cohort of contemporary HIV-infected U.S. adults, we sought
to examine the frequency and associated demographic, clinical, laboratory, and behavioral correlates of depression
among participants prescribed HAART and followed for 24
months, and to evaluate the association between depression
and adherence to HAART during the same period.
Methods
The SUN Study
The SUN Study is an ongoing, closed, prospective cohort
study of 700 HIV-infected patients receiving care at HIVspecialty clinics in Denver, Colorado; Minneapolis, Minnesota;
Providence, Rhode Island; and St. Louis, Missouri. Participants were enrolled between March 2004 and June 2006, and
were followed for up to 24 months thereafter. Detailed methods and inclusion criteria have been described elsewhere.47
The study protocol was approved and has been reviewed
annually by the institutional review boards of the Centers for
Disease Control (CDC) and all participating institutions. All
participants provided written, informed consent.
Study population
We restricted all analyses to HAART-treated participants
to examine risk factors for depression and the association
between depression and antiretroviral medication (ARV)
adherence within the same subset of participants followed
from baseline up to 24-month study visit. Of 700 SUN Study
participants, 539 were prescribed HAART and completed the
baseline Audio Computer-Assisted Self Interview (ACASI)
survey. The remaining patients were not included in this
study because they did not complete a baseline ACASI survey
data (n = 23) or were currently not prescribed HAART or were
ARV-naı̈ve (n = 138).
Measures
SUN Study participants completed an ACASI at enrollment
(baseline) and every 6 months thereafter; not all participants
completed ACASI at all timepoints. Information collected by
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ACASI included sociodemographic factors, education, employment status, tobacco, alcohol and drug use, sexual risk
behaviors, depressive symptoms, suicidal ideation, quality of
life, and adherence to antiretroviral medications. The ACASI
questionnaire could be taken in English or Spanish. To ensure
participant confidentiality and encourage self-disclosure of
accurate information, participants listened to questions alone
while logged onto a dedicated computer terminal in a private
area. All data collected from the ACASI were held confidentially and not shared with the participants’ healthcare providers. For this analysis, we examined ACASI data from
baseline through the 24-month study visit, as available. In
addition, we abstracted CD4 T-lymphocyte cell counts (CD4),
plasma HIV-1 RNA viral loads (HIV VL), diagnoses of depression and hepatitis C infection, and prescriptions given for
antiretroviral and antidepressant medication from participants’ medical records.
Definitions of the outcome variables
Depression by PRIME-MD. Depression was assessed
using the Patient Health Questionnaire (PHQ-9), also known
as PRIME-MD, which is a series of nine questions regarding
the frequency of depressive symptoms over the last 2 weeks
that has been validated for diagnosis of depression
(Table 1).43,45,46 Each question has four possible responses:
‘‘not at all,’’ ‘‘several days,’’ ‘‘more than half the days,’’ and
‘‘nearly every day.’’ Each response was scored from 0 to 3,

Table 1. PRIME-MD Instrument
for Depression Screening
Depression Screening Questions
Over the past 2 weeks, how often have you been bothered by
any of the following problems....?
1. Little interest or pleasure in doing things
2. Feeling down, depressed or hopeless
3. Trouble falling or staying asleep, or sleeping too much
4. *Feeling tired or having little energy
5. Poor appetite or overeating
6. Feeling bad about yourself—or that you are a failure or
have let yourself or your family down
7. Trouble concentrating on things such as reading the
newspaper or watching television
8. Moving or speaking so slowly that other people could
have noticed? Or the opposite-being so fidgety or restless
that you have been moving around a lot more than usual
9. Thoughts that you would be better off dead or hurting
yourself in some way.
*This question was omitted from the ACASI, in error, through the
end of 2006. For analyses at these time points, we instead used a
question in the ACASI asked in the following way: ‘‘How often in
the last 4 weeks have you had a lot of energy?’’ and coded that
variable in reverse fashion in the following manner:
0 All the time (tired = 0)
1 Most of the time (tired = 0)
2 A good bit of the time (tired = 0)
3 Some of the time (tired = 1)
4 A little of the time (tired = 2)
5 None of the time (tired = 3)
Sensitivity analyses at 24 months for participants who had both
original question #4 and substitute question, revealed that the
distribution of total depression scores was similar, and 96.5% (274/
284) of participants had concordant level of depression severity
(none, mild, moderately severe, severe).
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respectively. The total score could range from 0 to 27.
Depression severity was defined as none/minimal (total score
0–4), mild (total score 5–9), moderate (total score 10–14),
moderately severe (total score 15–19), and severe (total score
20–27), as previously reported.43,45,46 We defined major depression as (1) a score of 2 or 3 on four of the nine items,
including on each of the screener’s first two items; or (2) a
score of 2 or 3 on five of the nine items, including on at least
one of the screener’s first two items. Based on each patient’s
score at baseline or at any one of the subsequent 6-monthly
ACASI evaluations, the patient was assigned a binary depression outcome (yes or no) for his or her depression status at
that point in time; thus depression status could vary over time
(e.g., new onset, resolution, or intermittent depression).
Adherence to antiretroviral medication. Adherence to
antiretroviral medication was assessed from self-report on the
ACASI. Nonadherence was defined as having missed one or
more doses of prescribed antiretroviral medications in the
past 3 days.
Definitions of predictor variables and other covariates
Participants’ age, hepatitis C co-infection status (defined by
either serostatus or presence of the clinical diagnosis in the
medical records if serostatus was absent), marital status, and
type of health insurance were determined at the baseline SUN
Study visit. Employment status, drinking 3 or more alcoholic
drinks per day in the past 30 days, current tobacco use (‘Do
you currently smoke cigarettes?’), nonprescription drug use
in the past 6 months (an aggregate variable for use of cocaine,
heroin, injected drugs, methamphetamines, poppers, marijuana, erectile dysfunction agents, or a club or party drugs
[e.g., gamma hydroxybutarate, ketamine]), family history of
depression were updated every 6 months based on interval
ACASI responses. Receipt of antidepressants, CD4 count, and
HIV VL were updated every 6 months based on data abstracted from the medical records. Two clinicians reviewed
the medical records to confirm that antidepressant medications were prescribed for depression and not other uses (e.g.,
neuropathy, smoking cessation). HAART was defined as a
regimen comprised of ‡ 3 nucleoside reverse transcriptase
inhibitors or ‡ 3 antiretroviral drugs from at least 2 different
classes, as per SUN Study inclusion criteria.47
For repeated measures analyses (see Statistical Analyses
section, below), the closest value for each 6-month predictor
variable was taken from the same 6-month ACASI evaluation
as the binary outcome variable for depression status (yes/no)
at that point in time. For the plasma HIV VL and CD4 count,
the closest values from medical chart abstraction (within 12
months before up to 3 months after) to the 6-month ACASI
were used.
Statistical analyses
First, we described sociodemographic and clinical factors
associated with depression at baseline according to baseline
PRIME-MD score, overall and stratified by sex. Univariate
differences were assessed using the chi-square test (discrete
variables) or the Wilcoxon rank sum test (continuous variables). The chi-square test was used to test for trend. Second,
we performed two sets of longitudinal regression analyses: (i)
to identify patient-level factors associated with depression at a
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given ACASI evaluation, and (ii) to assess the association of
depression with nonadherence each defined at a given ACASI
evaluation, and adjusted for other patient-level covariables.
For both of these regression analyses we used data from the
baseline, 6-, 12-, 18- and 24-month ACASI, as available.
To account for the correlation between repeated ACASI
interview results for each participant, we used generalized
estimating equations (GEE) models, assuming a binomial
distribution for each of two outcome variables (depression,
adherence) in separate models; for each model, results
are reported as an odds ratio (OR) with associated 95%
confidence interval (CI). Variables possibly associated
(p < 0.10) with the outcome of interest in the univariate
analyses were included in multivariable models; separate
models were constructed for the outcomes of depression
and non-adherence.
We constructed separate models for predictors of depression in women and men, because in exploratory analyses the
associations between risk factors and depression varied by
sex, as did the prevalence of depression. By contrast, we
combined data from men and women when modeling the
association between depression and adherence, because we
did not observe marked differences in associations by sex.
We did not include HIV RNA (viral load, VL) as a predictor
variable in the models for depression and nonadherence as we
hypothesized it to be an outcome of depression and nonadherence rather than a predictor (i.e., reverse causal relationship). Final models were obtained by backward selection
and retained only predictor variables with a p value < 0.05.
Finally, we also described the association between prevalent
depression severity and the likelihood of having a suppressed
HIV VL (i.e., < 400 copies/mL) at that point in time. Analyses
were repeated using a viral suppression threshold of < 50
copies/mL after excluding the minority of patients who had
their viral load measured with assays with a lower limit of
detection of < 400 copies/mL and who had undetectable results (i.e., censored, non-evaluable data). All analyses were
conducted using SAS version 9.1 (SAS Institute, Cary, North
Carolina).
Results
Baseline
Of 539 participants, 21.2% were women, 60.9% white,
26.7% non-Hispanic black and 8.2% Hispanic (Table 2).
Overall, 75 (13.9%) participants had symptoms of depression
at baseline. Depression was more prevalent among women
(21.9%) compared with men (11.8%, p = 0.005) and among
non-Hispanic blacks (17.4%) and Hispanics (29.6%) compared
with non-Hispanic whites (10.7%) (race/ethnicity overall
comparison, p = 0.003). The prevalence of depression at baseline by sex and race/ethnicity is displayed in Fig. 1.
Other baseline characteristics associated with depression
(Table 2) included having no marital/sexual partner, heterosexual, or intravenous-drug-use (IDU) risk for HIV transmission versus men who have sex with men (MSM) risk,
hepatitis C co-infection, use of public insurance, and current
tobacco use. There was a decreasing frequency of depression
with increasing extent of employment; retired or other status
(27.3%), unemployed (21.9%), part-time employed (8.1%),
and full-time employed (6.1%) ( p < 0.001). Depression was
more frequent among participants with a family history of
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Table 2. Baseline Characteristics of the Study Population and Prevalence of Depression
for HAART-Treated Participants, the SUN Study, 2004–2006
No depression
N = 464
n (%)

Depressiona
N = 75
n (%)

113 (21.0)
231 (42.9)
195 (36.2)

101 (21.8)
191 (41.2)
172 (37.1)

12 (16.0)
40 (53.3)
23 (30.7)

10.6
17.3
11.8

425 (78.9)
114 (21.2)

375 (80.8)
89 (19.2)

50 (66.7)
25 (33.3)

11.8
21.9

144
44
23
328

(26.7)
(8.2)
(4.3)
(60.9)

119
31
21
293

(25.7)
(6.7)
(4.5)
(63.2)

25
13
2
35

(33.3)
(17.3)
(2.7)
(46.7)

17.4
29.6
8.7
10.7

71
260
92
63
63

(13.2)
(48.2)
(17.1)
(11.7)
(11.7)

63
217
82
43
59

(13.6)
(46.8)
(17.7)
(9.3)
(12.7)

8
43
10
10
4

(10.7)
(57.3)
(13.3)
(13.3)
(5.3)

11.3
16.5
10.9
18.9
6.4

Total
N = 539
n (%)
Age (baseline), years
< 35
35–44
‡ 45
Sex
Male
Female
Race/ethnicity
Non-Hispanic black
Hispanic
Other, or unknown
Non-Hispanic white
Marital status
Married
Single without a partner
Single with partner
Divorced, widowed or separated
Unknown
Partner status
Alone
Partner, or unknown
Employment status
Full time
Part time
Unemployed
Retired or other
HIV risk group
Heterosexual
IDU
MSM
Other
Insurance status
Private
Public
Other, or unknown
Tobacco use (current)
Yes
No
Drug use past 6 months
Yes
No
Alcohol use past 30 days
< 3 drinks per day
3 or more drinks per day
BMI (median), kg/m2
< 25
25–29.9
‡ 30
CD4 (median), cells/mm3
< 200
200–349
350–500
> 500
HIV viral load < 400 cp/mL
Yes
No
Median VL (log10 cp/mL) if viremic
Hepatitis C co-infection
Yes
No

% with
depression

p Value
0.136

0.005
0.003

0.152

0.017
313 (58.1)
226 (41.9)

260 (56.0)
204 (44.0)

53 (70.7)
22 (29.3)

16.9
9.7

262
62
96
119

(48.6)
(11.5)
(17.8)
(22.1)

246
57
75
86

(53.0)
(12.3)
(16.2)
(18.5)

16
5
21
33

(21.3)
(6.7)
(28.0)
(44.0)

6.1
8.1
21.9
27.3

132
36
322
49

(24.5)
(6.7)
(59.8)
(9.1)

107
27
289
41

(23.1)
(5.8)
(62.3)
(8.8)

25
9
33
8

(33.3)
(12.0)
(44.0)
(10.7)

18.9
25.0
10.3
16.3

< 0.001

0.016

0.043
219 (40.6)
178 (33.0)
142 (26.4)

196 (42.2)
144 (31.0)
124 (26.7)

23 (30.7)
34 (45.3)
18 (24.0)

10.5
19.1
12.7

233 (43.2)
306 (56.8)

182 (39.2)
282 (60.8)

51 (68.0)
24 (32.0)

21.9
7.8

277 (51.4)
262 (48.6)

232 (50.0)
232 (50.0)

45 (60.0)
30 (40.0)

16.3
11.5

392
147
25.6
240
195
104
455
60
129
120
228

338
126
25.6
210
169
85
465
51
108
101
203

< 0.001
0.108
0.879
(72.7)
(27.3)
(22.8,29.0)
(44.5)
(36.2)
(19.3)
(296,675)
(11.2)
(24.0)
(22.4)
(42.5)

(72.8)
(27.2)
(22.8, 29.0)
(45.3)
(36.4)
(18.3)
(299, 680)
(11.0)
(23.3)
(21.8)
(43.8)

54
21
25.8
30
26
19
403
9
21
19
25

(72.0)
(28.0)
(22.5, 30.0)
(40.0)
(34.7)
(25.3)
(239, 596)
(12.2)
(28.4)
(25.7)
(33.8)

13.8
14.3
12.5
13.3
18.3
15.0
16.3
15.8
11.0

476 (88.6)
61 (11.4)
3.2 (2.9,4.3)

414 (89.4)
49 (10.6)
3.3 (2.9,4.1)

62 (83.8)
12 (16.2)
3.2 (3.1,4.7)

13.0
19.7

72 (13.4)
467 (86.6)

53 (11.4)
411 (88.6)

19 (25.3)
56 (74.7)

26.4
12.0

0.713
0.350

0.058
0.440

0.156
0.814
0.001

(continued)
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Table 2. (Continued)
No depression
N = 464
n (%)

Depressiona
N = 75
n (%)

180 (33.4)
351 (65.1)
8 (1.5)

140 (30.2)
317 (68.3)
7 (1.5)

40 (53.3)
34 (45.3)
1 (1.3)

22.2
9.7
12.5

397 (73.7)
142 (26.3)

361 (77.8)
103 (22.2)

36 (48.0)
39 (52.0)

9.1
27.5

78 (14.5)
454 (84.2)
7 (1.3)

60 (12.9)
398 (85.8)
6 (1.3)

18 (24.0)
56 (74.7)
1 (1.3)

23.1
12.3
14.3

266 (49.4)
273 (50.6)

230 (49.6)
234 (50.4)

36 (48.0)
39 (52.0)

13.5
14.3

Total
N = 539
n (%)
Family history of depression
Yes
No
Missing
Prescribed antidepressant in the past 6 months
No
Yes
Missed dose of ARVs in the past 3 days
Yes
No
Missing
Time since HIV diagnosis (baseline)
< 5 years
‡ 5 years

% with
depression

p Value
< 0.001

< 0.001
0.041

0.801

a
Depression was defined based on the results from PRIME-MD screen, as described in the methods. ARV, antiretroviral therapy; BMI, body
mass index; HCV, hepatitis C virus; IDVU, injection drug users; MSM, men who have sex with men.

depression, and among participants prescribed antidepressants within 6 months prior to baseline. Participants who reported nonadherence to ARVs were more likely to have
depression than participants who did not or who were missing adherence data (23.1% vs. 12.3% vs. 14.3%, p = 0.04). There
were no significant differences in the frequency of depression
at baseline according to age, marital status, illicit or nonprescribed recreational drug use, body mass index (BMI),
CD4 count, or HIV VL.
Longitudinal correlates of depression
Of 539 patients who had baseline ACASI data available,
383 (71.1%) completed an ACASI at the 24-month study visit;
the remaining 156 (28.9%) participants were not surveyed

because they were lost to care (e.g., transferred to another HIV
clinic), died, or missed the 24-month study visit and did not
complete the ACASI. Among patients who completed the 24month study visit, 54 (14.1%) reported depression at baseline,
compared with 21 (13.5%) among patients who did not
complete the 24-month visit ( p = 0.84). Overall, 75 (13.9%) and
41 (10.7%) participants, at the baseline and 24-month visit,
respectively, reported depression by ACASI.
Among 539 patients included, 403 (74.8%) reported no
depression at baseline or during available follow-up visits
through 24 months (‘no evidence of depression’); 61 (11.3%)
reported no depression at baseline but depression on at least
one follow-up visit (‘potential depression onset’); 44 (8.2%)
reported depression at baseline and no depression on one or
more follow-up visits (‘intermittent or resolved depression’);

FIG. 1. Frequency of depression at baseline among HAART-experienced participants in the SUN Study, by sex and race/
ethnicity, 2002–2006 (n = 539).

SADNESS IN THE SUN

723

Table 3. Longitudinal Correlates of Depression by PRIME-MD, Baseline
to 24 Months of Observation in the SUN Study, 2004–2008
Women (N = 114)
Univariate
OR (95% CI)
Age (baseline), years
< 35
Referent
35–44
3.89 (2.01, 7.50)
‡ 45
2.91 (1.45, 5.84)
Race/ethnicity
White
Referent
Black
1.29 (0.74, 2.22)
Hispanic, other, or unknown
2.29 (1.18, 4.46)
Partner statusa (baseline)
Partner or unknown
Referent
No partner
1.62 (0.94, 2.78)
Employment status (closestb)
Full, part time
Referent
No job, retired, or other
18.20 (7.22, 45.87)
Insurance status (baseline)
Private, other, or unknown
Referent
Public
1.60 (1.01, 2.54)
Current tobacco use (current)
No
Referent
Yes
5.85 (3.93, 10.09)
Drug use in last 6 months
No
Referent
Yes
2.05 (1.27, 3.29)
Alcohol use past 30 days
< 3 drinks per day
Referent
3 or more drinks per day
1.58 (0.91, 2.75)
BMI, kg/m3
< 25
Referent
25–29.9
0.78 (0.44, 1.37)
‡ 30
0.60 (0.35, 1.03)
CD4 count (closestb)cells/mm3
< 200
3.50 (1.66, 7.37)
200–349
1.49 (0.81, 2.74)
350–500
1.48 (0.83, 2.64)
> 500
Referent
HCV (baseline)
No
Referent
Yes
3.51 (2.14, 5.74)
Family history of depression (closest)
No/unknown
Referent
Yes
1.89 (1.19, 2.97)
Prescribed antidepressant in the past 6 months
No
Referent
Yes
3.17 (1.53, 6.58)
Duration since HIV diagnosis (baseline)
< 5 years
Referent
‡ 5 years
1.57 (0.99, 2.48)

Men (N = 425)

Multivariable
OR (95% CI)

Univariate
OR (95% CI)

Multivariable
OR (95% CI)

Referent
2.19 (1.08, 4.46)c
1.46 (0.68, 3.17)

Referent
1.45 (0.91, 2.34)
1.54 (0.95, 2.47)

Referent
1.61 (0.88, 2.92)
3.43 (1.60, 7.37)c

Referent
1.86 (1.30, 2.66)
1.56 (0.99, 2.44)

Referent
2.03 (1.40, 2.94)c
1.75 (1.10, 2.78)c

Referent
1.71 (1.25, 2.34)

Referent
1.47 (1.06, 2.03)c

Referent
6.14 (4.41, 8.55)
Referent
1.77 (1.29, 2.42)
Referent
5.38 (3.01, 9.64)c

Referent
2.43 (1.79, 3.30)

Referent
2.24 (1.64, 3.07)c

Referent
1.23 (0.91, 1.66)
Referent
1.20 (0.88, 1.68)
Referent
1.06 (0.77, 1.47)
0.86 (0.53, 1.40)
3.84 (1.67, 8.81)c
1.36 (0.70, 2.62)
1.32 (0.70, 2.49)
Referent

1.67 (0.95, 2.92)
1.36 (0.91, 2.04)
1.37 (0.95, 1.99)
Referent
Referent
2.62 (1.79, 3.83)
Referent
1.91 (1.41, 2.60)

Referent
1.96 (1.42, 2.69)c

Referent
2.64 (1.67, 4.17)
Referent
0.75 (0.56, 1.02)

a
Includes marital status. Persons married or with a partner are categorized as having a partner; b‘‘Closest’’: means that data for this variable
were taken from the same (6-monthly) ACASI evaluation as the data for the depression outcome; for VL and CD4, take closest values from
the medical record (-1 year to + 3 month window). cStatistically significant association at p < 0.05.
BMI, body mass index; OR, odds ratio.

and 31 (5.8%) reported depression at baseline and on all their
follow-up visits through 24 months (‘persistent depression’).
In sex-specific univariate analyses for the 114 women and
425 men included in our analysis, the following factors were
significantly associated with depression for both sexes during
the 24 months of observation on HAART: unemployed or
retired employment status versus employed part or full time,

use of public insurance versus other forms of insurance or no
insurance, current tobacco use, hepatitis C co-infection, a
family history of depression, and receipt of antidepressant
medication in the past 6 months (Table 3). Furthermore,
among women, age 35 years and older, Hispanic race/ethnicity compared with non-Hispanic white, illicit or nonprescribed recreational drug use, as well as CD4 count < 200
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versus ‡ 500 cells/mm3, were associated with depression. In
men, non-Hispanic black race/ethnicity and no marital/
sexual partner were also associated with depression. In the
multivariable sex-specific analysis, a number of factors remained independently associated with risk of depression in
both groups, but certain further distinctions emerged. Among
women, depression was significantly associated with age
35–44 years compared with age < 35 years, Hispanic ethnicity
or other/unknown race compared with non-Hispanic white
race/ethnicity, current tobacco use, and CD4 count < 200
cells/mm3 compared with ‡ 500 cells/mm3. Among men,
factors associated significantly with depression included
black race and Hispanic ethnicity, having no marital/sexual
partner, current tobacco use, and family history of depression.
Association between depression
and nonadherence to ARVs
Nonadherence to ARVs was reported by 78 (14.5%) of the
539 participants at baseline and 60 (15.7%) of the 383 participants at the 24-month visit. Among participants with a 24month visit, 52 (13.6%) reported nonadherence to ARVs at
baseline compared with 26 (16.7%) among patients who did
not go on to complete a 24-month visit ( p = 0.38). In univariate
longitudinal analysis, depression of any severity on an ACASI
assessment was associated with approximately twofold
higher odds of nonadherence on the same ACASI assessment
(Table 4). Other factors associated with nonadherence in univariate analyses were female sex, non-white race or Hispanic
ethnicity, heterosexual and IDU risk group compared with
MSM, unemployment, public insurance, tobacco use, illicit
drug use, consumption of 3 or more alcoholic drinks daily, HIV
diagnosis ‡ 5 years, and CD4 count < 200 cells/mm3 compared
with ‡ 500 cells/mm3.
In the multivariable longitudinal analysis, participants who
reported mild or moderate levels of depression and persons
who reported moderately severe or severe depression had
higher odds of nonadherence (OR 2.02, 95% CI 1.15–3.57 and
OR 1.74, 95% CI 1.19–2.56, respectively) than participants
who were not depressed (Table 4). Other factors that remained independently associated with nonadherence were
female sex, non-Hispanic black and Hispanic or other race/
ethnicity, tobacco use, consuming ‡ 3 alcoholic drinks daily,
longer duration since HIV diagnosis, and CD4 count < 200
cells/mm3.
Association between depression
and virologic suppression
At baseline, the prevalence of viral suppression (HIV
VL < 400 copies/mL) among the 537 participants was 88.6%:
viral suppression was 89.4% among the 464 persons who were
not depressed, 84.2% among the 19 persons who were mildly
or moderately depressed, and 83.6% among the 56 moderately severely or severely depressed (test for trend p = 0.17). In
all time points after baseline, patients who reported any level
of depression had lower rates of virologic suppression (Fig. 2)
Discussion
This analysis based on data from a confidential selfadministered computerized standard screening instrument
administered to a contemporary and sociodemographically
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diverse cohort of HIV-infected patients in care extends previous findings that depression is prevalent, but not uniformly
distributed, among HIV-infected US patients in the HAART
era. We also found, as have others, a concerning association of
depression with nonadherence to antiretroviral therapy and
with lower levels of virologic suppression over 24 months of
follow-up.
Similar to the general population, HIV-infected SUN Study
participants who were most likely to be diagnosed as depressed were women and persons of color (Hispanics and
African-Americans).4 For ethnic minorities in the US, the
complex interaction of poverty, lifetime trauma, chronic illness, and illicit drug use result in a syndemic of HIV infection
and mental illness.48,49 We found that current tobacco smoking was associated with depression, potentially because tobacco use has been associated with poor socioeconomic and
psychosocial status. Factors such as unemployment and
having public health insurance, both of which are also generally associated with lower socioeconomic status, were associated with depression in the crude longitudinal analyses,
although they were not independently associated after adjustment for sex and race.
Among the most prevalent co-morbid chronic illnesses in
HIV-infected adults that can increase the risk for depression
and poor clinical outcomes is hepatitis C infection. Hepatitis C
infection itself leads to recognized neurologic sequelae including depression.50 In our baseline analysis, the frequency
of depression was high among HIV-infected participants coinfected with hepatitis C (26.4%). Hepatitis C co-infection was
not associated with depression in multivariable analyses in
our study, but has been independently prognostic of depression in other HIV cohorts.51,52
We performed separate analyses by sex to elucidate factors
associated with the high rates of depression in women. While
Hispanics and non-Hispanic blacks were more likely to be
depressed overall, Hispanic women had the highest rates of
depression (as shown in Fig. 1). What accounts for the higher
rate in Hispanics may not be discernible in the study, although the possibility that the computerized PHQ screening
instrument in Spanish actually identified more depressed
women is an intriguing possibility. Women with CD4 counts
below 200 cells/mm3, those using tobacco, and the ‘‘middleaged’’ group of 35- to 44-year-olds were among those most
likely to be depressed. Among the already vulnerable, these
depressed women may be at particular risk to be nonadherent
to medication. The interplay with depression and adherence
at lower CD4 strata can result in a cycle of more symptomatic
HIV disease or disease progression.53,54 In the Women’s Interagency HIV Study, depression, early discontinuation of
HAART, low income, illicit drug use and smoking were associated with worse clinical outcomes.55
In the present analysis, we found that nonadherence to
HAART over 24-months of follow-up was also associated
with depression, after controlling for other independent risk
factors that included female sex, being a person of color, retired or ‘other’ (not full- or part-time) employment status,
tobacco use, drinking 3 or more alcoholic beverages per day,
having been diagnosed with HIV infection ‡ 5 years ago, and
a CD4 cell count < 200 versus > 500 cells/mm3. Sociodemographic correlates of nonadherence have been studied
extensively in HIV-infected patients, and others have linked
nonadherence to non-white race, alcohol and illicit drug use,

Table 4. Longitudinal GEE Analyses of Depression and Other Factors Associated
with Nonadherence to Antiretroviral Therapy, SUN Study, 2004–2008
Univariate
OR

Multivariable
95% CI

Age (baseline), years
< 35
Referent
35–44
1.12
‡ 45
0.82
Sex
Male
Referent
Female
2.09
Race/ethnicity
Non-Hispanic black
2.12
Hispanic/other
1.68
Non-Hispanic white
Referent
Partner statusb
Alone
1.15
Partner or unknown
Referent
Employment status (closest)c
Full time
Referent
Part time
1.33
Unemployed
2.48
Retired or other
1.21
HIV risk group
Heterosexual
1.82
IVDU
2.43
MSM
Referent
Other or unknown
1.45
Insurance status (baseline)
Private or other
Referent
Public
1.73
Current tobacco use
No
Referent
Yes
1.92
Drug use past 6 months
Yes
1.29
No
Referent
Alcohol use past 30 days
< 3 drinks/day
Referent
3 or more drinks/day
1.69
BMI, kg/m3
< 25
Referent
25–29.9
0.80
‡ 30
0.83
CD4 count, cells/mm3
< 200
3.16
200–349
1.26
350–500
1.22
> 500
Referent
HCV (baseline)
No
Referent
Yes
1.81
Prescribed antidepressant in the past 6 months
Yes
1.13
No
Referent
Duration since HIV diagnosis (baseline)
< 5 years
Referent
‡ 5 years
1.33
Depression by PRIME-MD (closest)c
None
Referent
Mild or moderate
2.52
Moderately severe or severe
2.14

OR

95% CI

Referent
1.62, 2.69a

Referent
1.71

Referent
1.28, 2.28a

1.64, 2.73a
1.19, 2.36a
Referent

1.59
1.49
Referent

1.18, 2.14a
1.04, 2.14a
Referent

Referent
1.06
1.36
0.60

Referent
0.73, 1.54
0.96, 1.93
0.42, 0.87a

Referent
1.66

Referent
1.28, 2.15a

Referent
1.66

Referent
1.28, 2.15a

3.13
1.25
1.23
Referent

2.07, 4.73a
0.90, 1.74
0.90, 1.66
Referent

Referent
1.06, 1.67a

Referent
1.45

Referent
1.13, 1.86a

Referent
1.42, 4.28a
1.52, 3.00a

Referent
2.02
1.74

Referent
1.15, 3.57a
1.19, 2.56a

Referent
0.82, 1.52
0.60, 1.14

0.91, 1.45
Referent
Referent
0.93, 1.91
1.84, 3.36a
0.90, 1.64
1.40, 2.36a
1.60, 3.70a
Referent
0.95, 2.21
Referent
1.37, 2.19a
Referent
1.52, 2.41a
1.03, 1.62a
Referent
Referent
1.33, 2.16a
Referent
0.62, 1.03
0.61, 1.14
2.14, 4.64a
0.93, 1.72
0.91, 1.63
Referent
Referent
1.35, 2.43a
0.80, 1.59
Referent

a
Statistically significant association at p < 0.05; bIncludes marital status. Persons married or with a partner are categorized as having a
partner; c‘‘Closest’’: means that data for this variable were taken from the same (6-monthly) ACASI evaluation as the data for the depression
outcome; for VL and CD4, closest values were taken from the medical record (-1 year to + 3 month window).
ARV, antiretroviral therapy; BMI, body mass index; HCV, hepatitis C virus; IDVU, injection drug users; MSM, men who have sex with
men.
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FIG. 2. Percentage of patients with suppressed viral load (< 400 copies/mL) by depression level and follow-up time, SUN
Study, 2004–2006.
and longer duration of HIV infection. In a previously reported
baseline cross-sectional analysis in the SUN Study cohort,
nonadherence has been associated with black race, unemployment, HIV diagnosis ‡ 5 years , drinking 3 or more alcoholic beverages per day, and having not engaged in aerobic
exercise in the last 30 days.56
The association of depression with nonadherence to ARVs in
our study is also consistent with findings from prior studies,
which used a variety of methods for ascertaining depression.22,57–59 Indeed, depression of any severity observed among
SUN Study participants was associated with nonadherence;
even mild and moderate levels of depression doubled the odds
of reporting nonadherence. Given the increased risk for HIV
disease progression and mortality (due to AIDS-related and
non-AIDS-related causes) associated with suboptimal adherence
and lack of virologic suppression, these findings are concerning.
In this study, we administered the PRIME-MD standard
depression screening instrument as part of an ACASI performed in the primary HIV care setting. The self-administration aspect of the technology enabled the collection of data in
busy clinical settings as well as the ability to interview Spanish
speaking patients. Such longitudinal data in a diverse population have not been described extensively. The data collected
by ACASI are valuable in the management of HIV-infected
patients, providing the ability to screen and identify depressed
patients, elicit correlates of depression, and assess the potential
impact of depression on adherence to prescribed care.
Our findings are subject to several limitations. Even in these
integrated care settings, 28.9% of participants did not complete all the required visits and scheduled ACASIs. Loss to
follow-up and resultant missing data could introduce a bias,
particularly in the observed association of depression and
nonadherence. In the SUN Study, the documentation of diagnoses of depression in medical charts was not standardized
across participating sites. Participants could also have been
receiving mental health services elsewhere and these data

were not captured in their clinical record at the study clinic.
Because of incomplete medical charting, we could not reliably
ascertain the utility of using PRIME-MD for improving the
diagnosis of depression in routine HIV clinical practice. Additionally, although the PRIME-MD instrument was developed to provide diagnostic criteria for depression and has
been validated, it is possible that participants who reported
depression on PRIME-MD might not have met the criteria for
clinical diagnosis of depression by a physician.60 Furthermore, because no systematic interventions based on PRIMEMD results were implemented (i.e., clinicians were blinded to
the patients’ individual responses and could not use these
data to assess and treat), we could not evaluate whether recognition and treatment of depressed patients at high risk for
nonadherence could result in better immunologic and virologic outcomes, as has been suggested previously.31
Collection of depression, nonadherence, and other patient
risk factor data in a confidential fashion through ACASI
compared to other self-report instruments or specific interview methods has been reported in only a limited number of
U.S. HIV cohort studies.11,19,39 While findings to date tend to
be consistent in cross-sectional versus longitudinal analyses of
depression and adherence, the SUN cohort is one of few
studies that provides ongoing data collection from a diverse
cohort in a high-resource setting. This study underscores the
observation that depression and adherence are dynamic
processes that vary over time. One potential application for
future research is to evaluate the real time integration of an
ACASI-based PRIME-MD screening with an on-site behavioral health consultant or specific behavioral intervention and
systematic monitoring of changes in adherence.
In summary, the use of a confidential standardized computer-based screening instrument identified depression in over
10% of men and over 20% of women prescribed HAART; these
persons were in turn at higher risk of nonadherence to antiretroviral therapy and of not suppressing plasma HIV
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replication. Our findings and those of others suggest that
treating depression would not only improve quality of life but
would also likely improve survival by increasing adherence to
HAART, viral suppression, and CD4 cell counts. Improvement
in health outcomes for the HIV-infected community through
systematic attention to depression can also achieve one of the
goals of the current United States HIV/AIDS strategy.61 Although we could not determine whether depression was underdiagnosed in our population, we believe our findings provide
further compelling evidence for ensuring that contemporary
HIV-infected patients who are engaged in care are regularly
screened for depression and treated, if indicated.
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